key: cord-1019451-lecip329
authors: Fenollar, Florence; Thomas, Laurence; Raoult, Didier; Gautret, Philippe
title: Screening for SARS-CoV-2 antibodies to save vaccine doses
date: 2022-04-12
journal: Vaccine
DOI: 10.1016/j.vaccine.2022.04.028
sha: 0023b8f2635eaf30aa9ddbacba8242b473650809
doc_id: 1019451
cord_uid: lecip329

nan

Key words: COVID-19; SARSCoV-2; serology; screening; vaccine To the Editor We read with interest the paper by Ferrari et al. [1] showing that previously SARS-CoV-2 infected individuals had a strong humoral immune response after a first dose of COVID-19 vaccine suggesting that a single dose of vaccine should be proposed to seropositive doses for those in need [2] . In a serological surveillance study conducted in the Provence-Alpes-Côte d'Azur region, from May, 11 to May 17 2020, 3.3% of 397 individuals tested positive [3] .

In our vaccination center we implemented a pre-vaccination serological screening strategy starting on May 10, 2021 and provide here an interim analysis of results until June 15, 2021.

All persons consulting for a first dose of vaccine against COVID-19 were proposed a rapid whole-blood finger-stick immune-chromatographic serologic test (Biosynex COVID-19 BSS, 3 3 SW40005, Biosynex, Switzerland). The BioSynex test was selected because of its good sensitivity and specificity reported previously. [4, 5] . Data presented herein were collected retrospectively from the routine care setting using the electronic health recording system of the hospital. To conclude, the benefit of systematically screening individuals before a first dose of COVID-19 vaccine appears to be limited, in our experience, allowing saving less than 2% vaccine doses. Comparison with similar studies conducted in area with a higher incidence of COVID-19 will be of interest.

Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects

Décision n° 2021.0139/DC/SEESP du 31 mai 2021 du collège de la Haute Autorité de santé complétant les recommandations du 11 février 2021 relatives à « la vaccination des personnes ayant un antécédent de Covid-19

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies

Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests

☑ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work

FF, DR and PG contributed to the experimental design, data analysis, statistics, interpretation and writing. LT coordinated the laboratory work.

This study was supported by the Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, the National Research Agency under the "Investissements d'avenir" programme, reference ANR-10-IAHU-03, the Région Provence Alpes Côte d'Azur and European funding FEDER PRIMI.

No conflicts of interest have been reported by the authors.

Data available on request.